Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 143.71 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 0.00 shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 143.71K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 24.26K shares, a 98.19% decline from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 1.34M shares, a 68.14% decline from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 4.20M shares, a 32.31% increase from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 3.17M shares, a 6444.60% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 143.71K shares 10-Q · filed 2026-08-13 | 143.71K shares derived: sum of 3 quarters · filed 2026-08-13 | 143.71K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 143.71K shares 10-Q · filed 2026-05-14 | 143.71K shares derived: sum of 2 quarters · filed 2026-05-14 | 143.71K shares derived: sum of 3 quarters · filed 2026-05-14 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-23 | 24.26K shares 10-K · filed 2026-03-23 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 24.26K shares 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 24.26K shares 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | 8.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 54.75K shares derived: sum of 2 quarters · filed 2025-03-18 | 150.28K shares derived: sum of 3 quarters · filed 2025-03-18 | 1.34M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 46.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 141.95K shares derived: sum of 2 quarters · filed 2024-11-12 | 1.33M shares 10-Q · filed 2024-11-12 | 1.88M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 95.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.28M shares 10-Q · filed 2024-08-14 | 1.83M shares derived: sum of 3 quarters · filed 2024-08-14 | 2.60M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 1.19M shares 10-Q · filed 2024-05-14 | 1.74M shares derived: sum of 2 quarters · filed 2024-05-14 | 2.50M shares derived: sum of 3 quarters · filed 2024-05-14 | 2.51M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 547.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 1.31M shares derived: sum of 2 quarters · filed 2024-03-21 | 1.32M shares derived: sum of 3 quarters · filed 2024-03-21 | 4.20M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 765.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 773.42K shares derived: sum of 2 quarters · filed 2023-11-07 | 3.65M shares 10-Q · filed 2023-11-07 | 3.71M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 8.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 2.89M shares 10-Q · filed 2023-08-11 | 2.94M shares derived: sum of 3 quarters · filed 2023-08-11 | 3.24M shares derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | 2.88M shares 10-Q · filed 2023-05-11 | 2.93M shares derived: sum of 2 quarters · filed 2023-05-11 | 3.24M shares derived: sum of 3 quarters · filed 2023-05-11 | 3.97M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 52.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 356.19K shares derived: sum of 2 quarters · filed 2023-03-22 | 1.09M shares derived: sum of 3 quarters · filed 2023-03-22 | 3.17M shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 303.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 1.04M shares derived: sum of 2 quarters · filed 2022-11-01 | 3.12M shares 10-Q · filed 2022-11-01 | |
| 2022-06-30 | 735.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 2.82M shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 2.08M shares 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 48.51K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |